

Señor Director

DIRECCION DE NUEVAS CREACIONES

Superintendencia de Industria y Comercio

E. S. D.

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 11-133740- -00007-0000

Fecha: 2013-02-21 16:37:16 Dep. 2020 DIR.NUEVASCREA
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 449 RESPUESOPOSICI Folios: 16

Trámite : 011

Evento : 378

Actuación : 449

Referencia : Expediente No. **11.133.740**

Asunto : Solicitud de patente para: **COMPOSICIONES FARMACÉUTICAS DE LIBERACIÓN INMEDIATA QUE COMPRENDEN OXICODONA Y NALOXONA**

Solicitante : **EURO-CELTIQUE S.A.**

Opositor : **LABORATORIOS SYNTHESIS S.A.S.**

1. ALEGATOS CONTESTACIÓN OPOSICIÓN

Yo, Luz Clemencia de PAÉZ, en mi condición de apoderada de la sociedad solicitante **EURO-CELTIQUE S.A.**, por el presente escrito doy respuesta a la oposición formulada por la sociedad **LABORATORIOS SYNTHESIS S.A.S.**, representada por la doctora Eliana Isaura Moreno Bohórquez, contra la solicitud de patente para la invención **COMPOSICIONES FARMACÉUTICAS DE LIBERACIÓN INMEDIATA QUE COMPRENDEN OXICODONA Y NALOXONA** que se tramita en el expediente de la referencia.

2. CONTESTACIÓN DENTRO DEL TÉRMINO LEGAL

El oficio No. **15459**, mediante el cual ese Despacho dispuso otorgar a mi representada término para presentar sus argumentaciones a favor de la patentabilidad del invento de que trata el asunto en referencia, me fue notificado por fijación en lista el 4 de septiembre de 2012. Para atender a la mencionada providencia solicité un plazo adicional de sesenta (60) días mediante memorial radicado el 21 de noviembre de 2012. Por lo tanto, la presente defensa es presentada en tiempo oportuno.

"EXCELENCIA LEGAL EN UN MUNDO SIN FRONTERAS"

BOGOTÁ - Edificio Siski - Carrera 4 No. 72 - 35 - Tel. (57-1) 347 3611 - Fax (57-1) 211 8650 - Fax in U.S.A.: (1-305) 675 7743 - COLOMBIA
MEDELLÍN - San Fernando Plaza - Carrera 43 A No. 1 - 50 - Torre Protección Oficina 652 - Tel: (57-4) 604 4794 Ext. 6729 / 6731 - Fax: (57-4) 604 4731- COLOMBIA

www.cavelier.com
cavelier@cavelier.com

3. RESPUESTA A LAS PETICIONES

Me opongo a las peticiones de la sociedad **LABORATORIOS SYNTHESIS S.A.S.** y en consecuencia solicito se declare infundada la oposición presentada y se otorgue el privilegio de patente para la invención **COMPOSICIONES FARMACÉUTICAS DE LIBERACIÓN INMEDIATA QUE COMPRENDEN OXICODONA Y NALOXONA** a nombre de la sociedad **EURO-CELTIQUE S.A.** tramitada bajo el expediente de la referencia.

4. FUNDAMENTO FÁCTICO DE LA OPOSICIÓN

Fundamenta el opositor su petición, en los siguientes argumentos principales:

4.1 Antes de la fecha de prioridad de la presente solicitud, se encuentra el siguiente documento que afectan la patentabilidad de la presente solicitud:

D1: EP1695700 publicada el 30 de agosto de 2006.

4.2 El documento D1 se refiere a una forma de dosificación que comprende oxicodona y naloxona, que se caracteriza por específicos parámetros in vivo tales como t max, C max, valor AUCt, la puntuación media función intestinal y/o duración de la eficacia analgésica. De manera particular el documento revela una composición de oxicodona y naloxona en una forma de liberación prolongada.

4.3 Por lo tanto, la solicitud objeto de oposición, a la luz del documento D1 carece de altura inventiva, dado que un experto en la materia puede llegar de manera evidente a una composición farmacéutica oral de liberación inmediata, que comprende al menos oxicodona o una sal farmacéuticamente aceptable de la misma y naloxona o una sal farmacéuticamente aceptable de la misma, donde la composición está en forma sólida, sobre lo cual busca protección en el capítulo reivindicatorio..

5. RESPUESTA A LOS HECHOS Y ALEGATOS

5.1 Me permito presentar a consideración de este Despacho, las razones que demuestran que es procedente otorgar privilegio de patente a la invención solicitada por mi representada en este asunto, toda vez que la invención revelada en el pliego reivindicatorio no infringe las normas citadas por la apoderada de la sociedad opositora como sustento de sus pretensiones, como ninguna otra establecida en nuestro ordenamiento vigente.

5.2. Señala el opositor que la invención solicitada no cumple con el requisito de nivel inventivo, presupuesto establecido en el artículo 18 de la Decisión 486 de la Comisión de la Comunidad Andina; esta norma dispone:

Artículo 18.- *Se considerará que una invención tiene nivel inventivo, si para una persona del oficio normalmente versada en la materia técnica correspondiente, esa invención no hubiese resultado obvia ni se hubiese derivado de manera evidente del estado de la técnica.*

El requisito de “nivel inventivo”, surge al considerar que una invención implica una actividad inventiva, si aquella no resulta del estado de la técnica de una manera evidente para un experto en la materia. Adicionalmente, es claro que para la evaluación de nivel inventivo los documentos citados deben revelar sugerencias y enseñanzas claras para el técnico en la materia que lo lleven a obtener la presente invención.

Del mismo modo, el Examinador al realizar el examen de nivel inventivo debe verificar las enseñanzas del arte previo sin adoptar la posición de un inventor que se preguntaría cómo solucionar el problema técnico en cuestión. Lo anterior, por cuanto si se adopta la posición del inventor y se tiene conocimiento tanto del arte previo como de la forma como efectivamente se solucionó el problema técnico, la invención en todos los casos le resultará obvia y evidente.

5.3 Ahora bien, teniendo en cuenta lo anterior es claro que la presente invención es inventiva frente al documento D1 citado por la parte opositora porque la misma no se deriva de manera obvia u evidente a partir de dicho documento. Veamos:

5.3.1 En primer lugar, solicito a ese Despacho tener en cuenta que la invención cuya protección se solicita en el presente expediente y de manera particular las dos reivindicaciones independientes del pliego reivindicatorio actualmente en estudio, se refieren a composiciones farmacéuticas de liberación inmediata que contienen oxicodona y naloxona.

La reivindicación 1 está dirigida a composiciones orales de liberación inmediata que contienen oxicodona y naloxona (o sales de las mismas) en una proporción de aproximadamente 2:1, mientras que la reivindicación 19 está dirigida a composiciones orales de liberación inmediata que contienen oxicodona y naloxona (o sales de las mismas) que liberan más de o lo equivalente al 90% de oxicodona y naloxona en una prueba in vitro a los 15 minutos.

En la página 2, líneas 5 a 8 de la Publicación Internacional WO 2010/103039, correspondiente a la presente fase nacional, las formas de dosificación reivindicadas pueden ser utilizadas de manera particular para tratar a pacientes que sufren de dolores y/o para tratar el dolor irruptivo en pacientes, simultáneamente evitando la aparición de efectos secundarios

no deseados (tales como el estreñimiento o retención urinaria, ver página 24, líneas 23 y 24 de la mencionada Publicación Internacional). La forma de dosificación reivindicada en la reivindicación 19 es particularmente adecuada para tratar a pacientes como niños o personas mayores que puedan tener problemas con la ingestión de una forma de dosificación, ya que la forma de dosificación de la reivindicación 19 puede disolverse rápidamente en líquido o colocarse en la boca para su rápida disolución, permitiendo así una fácil administración por vía oral a dichos pacientes (ver página 26, líneas 1 a 7 de WO 2010/103039). Claramente, dichas formas de dosificación son particularmente adecuadas para tratar los ataques de dolor repentinos.

Por lo tanto, **la presente invención hace referencia a formas de dosificación orales que comprenden oxicodona y naloxona, de donde la oxicodona y la naloxona se liberan de manera inmediata, en donde las formas de dosificación son particularmente adecuadas para tratar el dolor irruptivo al mismo tiempo evitando la aparición de efectos secundarios no deseados de una terapia contra el dolor a base de opiode.**

Debido a que se puede lograr una analgesia inmediata y eficaz mediante la agonista opiode de oxicodona comprendida en las formas de dosificación de la presente invención, no parece haber ninguna influencia ejercida por el antagonista opiode naloxona en la analgesia proporcionada por la oxicodona. Esto se explicará más detalladamente a continuación.

5.3.2 Solicito a ese Despacho tener en cuenta que aún cuando en el escrito de oposición presentado por LABORATORIOS SYNTHESIS S.A.S. se cita un documento del estado del arte, no se sigue el procedimiento para determinar si la invención cumple con el requisito de nivel inventivo, pues no revela las sugerencias y enseñanzas claras para el técnico en la materia que lo llevarían a obtener la misma.

Así entonces, se debe concluir que para ser pertinentes en la evaluación del nivel inventivo de la presente invención, la parte opositora debió señalar las partes del documento más cercano del estado del arte, donde se revelen las sugerencias y enseñanzas claras para el técnico en la materia que lo llevarían a obtener la misma.

Así, la sociedad opositora simplemente señala que D1 revela formas de dosificación de liberación prolongada que comprenden oxicodona y naloxona. Sin embargo, la sociedad opositora no proporciona ningún argumento de fondo que explique exactamente por qué es supuestamente obvio llegar a una forma de dosificación de liberación inmediata que comprende oxicodona y naloxona a partir de las enseñanzas de D1 de una forma de dosificación de liberación prolongada que comprende oxicodona y naloxona.

A este respecto, manifiesto a ese Despacho que mi representada está de acuerdo con la sociedad opositora en que el documento citado como anterioridad D1 hace referencia a

formas de dosificación de liberación sostenida que comprenden oxicodona y naloxona que generan un efecto analgésico de larga duración (ver párrafo entre otros [0029] o [0039] y todos los ejemplos de D1). Las formas de dosificación conforme a D1 son por lo tanto particularmente adecuadas en la terapia contra el dolor crónico, al mismo tiempo evitando y/o tratando los efectos secundarios asociados a la terapia de opiode (ver párrafos entre otros [0030] y [0031] de D1).

Sin embargo, D1 **no proporciona ningún indicio de que la oxicodona y la naloxona también pueden ser utilizadas con éxito en una forma de dosificación de liberación inmediata, es decir, para el tratamiento de ataques de dolor repentinos (“dolores irruptivos”), al mismo tiempo manteniendo los efectos ventajosos alcanzados con la combinación de oxicodona y naloxona.** Por lo tanto, la invención que se tramita en el presente expediente goza del requisito de nivel inventivo.

5.3.3 Adicionalmente, es preciso señalar que el estado de la técnica enseña a no incluir naloxona en una forma de liberación inmediata en una forma de dosificación que contiene un agonista opiode.

Tal y como se mencionó anteriormente, D1 hace referencia a formas de dosificación que liberan tanto oxicodona y naloxona de manera sostenida. Esto lleva a la terapia eficaz para el alivio del dolor crónico, al mismo tiempo evitando la aparición de efectos secundarios del agonista opiode de oxicodona (ver página 23, líneas 7 a 26 de WO 2010/103039 para una discusión sobre las formas de dosificación de liberación prolongada que comprenden oxicodona y naloxona de D1). En las formas de dosificación conforme a D1, la analgesia se alcanza con la oxicodona. La naloxona como antagonista opiode está presente en la forma de dosificación con el fin de antagonizar localmente los efectos de la oxicodona en el tracto gastrointestinal, de tal manera que se contrarresta particularmente el estreñimiento como efecto secundario de la oxicodona. Como la naloxona se somete a un efecto de primer paso hepático significativo, está sistémicamente presente en una forma inactiva que no contrarresta/antagoniza la actividad analgésica sistémica de la oxicodona. Tal actividad contrarrestante/antagonista puede resultar en síntomas de abstinencia de opiáceos indeseables.

Para el caso de D1, se asumió que liberación sostenida de la naloxona es particularmente importante para asegurarse de que la naloxona sea eficazmente inactivada por el hígado, de tal manera que no llegue a ser sistémicamente activa. Esto se puede derivar de una publicación científica relacionada al concepto de D1, en donde los autores manifiestan lo siguiente (ver página 63, columna derecha, último párrafo de la publicación de *Meissner-2009*, copia adjunta a este escrito):

“El uso de naloxona oral de liberación inmediata se estudió anteriormente para determinar sus efectos en la reducción del estreñimiento inducido por opioides; sin embargo, las poblaciones de estudio han sido pequeñas y los resultados equívocos (Sykes, 1996; Meissner et al., 2000; Liu y Wittbrodt, 2002; Latasch et al., 1997). En algunas de estas pruebas se observaron síntomas de abstinencia aun en dosis bajas de naloxona oral. En la prueba actual se utilizó PR-naloxona. La liberación lenta de la naloxona podría reducir el riesgo de sobrecarga de los sistemas enzimáticos hepáticos responsables de su metabolismo, reduciendo así el riesgo de antagonismo sistémico.”

Lo anterior permite observar que, al usar naloxona de liberación inmediata se han observado síntomas de abstinencia, en algunos de los estudios previos. Este efecto no se observa en el estudio Meisser con naloxona de liberación prolongada en combinación con oxicodona de liberación prolongada. La publicación Meissner-2009 ha sido mencionada en la presente solicitud (ver página 23, línea 25 de la Publicación Internacional WO 2010/103039). Adicionalmente, los datos analizados en Meissner-2009 y el ejemplo 1 de D1 son idénticos.

Por lo tanto, el elemento caracterizante de la invención que se tramita en el presente expediente, del descrito en el documento citado como anterioridad por la sociedad opositora, D1, es que tanto la oxicodona como la naloxona se liberan de manera inmediata de la forma de dosificación.

Adicionalmente se ha encontrado de manera sorprendente que la naloxona, si se libera de forma inmediata de una forma de dosificación que también comprende oxicodona de liberación inmediata, aparentemente no tiene un impacto negativo en la analgesia, por ejemplo la naloxona aparentemente no induce síntomas de abstinencia. Esto también se describe en la Publicación Internacional WO 2010/103039 en la página 24, líneas 10 y 11: *“...el hecho de que el efecto de primer paso de naloxona también se mantenga para la formulación de liberación inmediata...”*.

Por lo tanto la forma de dosificación tal como ha sido reivindicada en la presente solicitud, puede por lo tanto ser exitosamente utilizada para tratar dolor irruptivo inter alia evitando efectos secundarios indeseables durante el tratamiento del dolor.

Finalmente, es preciso señalar que ya que el estado de la técnica señaló la importancia de la liberación prolongada de naloxona para evitar un impacto negativo de naloxona en la analgesia inducida por opioides, la persona experta en la materia no fue guiada hacia la presente invención y, por lo tanto, esta invención tal como se reivindica goza indiscutiblemente del requisito de nivel inventivo.

5.3.4 Por lo anterior, solicito a ese Despacho reconocer que teniendo en cuenta que las enseñanzas de la anterioridad citada no llevan a un técnico versado en la materia a obtener la presente invención, este documento **no** es una anterioridad válida que pueda afectar el nivel inventivo de la presente solicitud.

6. PETICIONES

Con fundamento en lo anterior solicito a ese Despacho lo siguiente:

6.1 Declarar infundada la oposición presentada por **LABORATORIOS SYNTHESIS S.A.S.**

6.2 Declarar que el invento titulado **COMPOSICIONES FARMACÉUTICAS DE LIBERACIÓN INMEDIATA QUE COMPRENDEN OXICODONA Y NALOXONA** para el cual mi representada solicita el otorgamiento de la patente de invención cumple con los requisitos del artículo 14, 16 y 18 concordantes de la Decisión 486 de la Comisión de la Comunidad Andina y otorgar el privilegio de patente solicitado.

7. ANEXOS

7.1 European Journal of Pain. "A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation". Winfried Meissner y otros. (2009).

8. NOTIFICACIONES

Mi representada y yo recibiremos notificaciones en la Secretaría de su Despacho o en mi oficina de abogada ubicada en la Carrera 4ª No. 72-35 de la ciudad de Bogotá, D.C.


Señor Director,


LUZ CLEMENCIA DE PAÉZ

C.C. 35.456.344 de Usaquén

T.P.A. No. 23.555

266
COLO-13416-0841-005-5
COLO-13416-0264-001-2
JGGJGG\ID-236514\WPC13416
No. M-2013-236514JGG



A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation

Winfried Meissner^a, Petra Leyendecker^{b,*}, Stefan Mueller-Lissner^d, Joachim Nadstawek^e, Michael Hopp^b, Christian Ruckes^b, Stefan Wirz^e, Wolfgang Fleischer^b, Karen Reimer^{b,c}

^a Clinic of Anaesthesiology and Intensive Care, Friedrich-Schiller-University, 07740 Jena, Germany

^b Mundipharma Research GmbH & Co. KG, 65549 Limburg (Lahn), Germany

^c University Witten/Herdecke, 58448 Witten, Germany

^d Park-Klinik Weissenau, 13086 Berlin, Germany

^e Clinic of Anaesthesiology and Intensive Care Medicine, University of Bonn, 53131 Bonn, Germany

ARTICLE INFO

Article history:

Received 25 September 2007

Received in revised form 5 June 2008

Accepted 30 June 2008

Available online 31 August 2008

Keywords:

Oxycodone

Naloxone

Opioid-induced constipation

Bowel function

Analgesia

ABSTRACT

Background: Opioid-induced constipation can have a major negative impact on patients' quality of life. This randomised, double-blinded study evaluated the analgesic efficacy of prolonged-release (PR) oral oxycodone when co-administered with PR oral naloxone, and its impact on opioid-induced constipation in patients with severe chronic pain. Another objective was to identify the optimal dose ratio of oxycodone and naloxone.

Methods: A total of 202 patients with chronic pain (mainly non-cancer related, 2.5% of patients had cancer-related pain) under stable oral oxycodone therapy (40, 60 or 80 mg/day) were randomised to receive 10, 20, 40 mg/day naloxone or placebo. After a 4-week maintenance phase, patients received oxycodone only for 2 weeks. Pain intensity was evaluated using a numerical analogue scale and bowel function was assessed using the bowel function index.

Results: No loss of analgesic efficacy with naloxone was observed. Mean pain intensity scores on randomisation were comparable for placebo, 10 mg, 20 mg and 40 mg naloxone dose, and remained unchanged during treatment. Bowel function improved with increasing naloxone dose. Naloxone 20 mg and 40 mg significantly improved bowel function at the end of the maintenance phase compared with placebo ($p < 0.05$). Overall, the combination was well tolerated, with no unexpected adverse events. There was a trend towards an increased incidence of diarrhoea with higher doses of naloxone. The 2:1 oxycodone/naloxone ratio was identified as the most suitable for further development.

Conclusion: Co-administration of PR oral naloxone and PR oral oxycodone is associated with a significant improvement in bowel function compared with PR oral oxycodone alone, with no reduction in the analgesic efficacy of oxycodone.

© 2008 European Federation of Chapters of the International Association for the Study of Pain. Published by Elsevier Ltd. All rights reserved.

1. Introduction

Oxycodone is a strong, semi-synthetic, well established opioid analgesic that has been in clinical use since 1917 for the treatment of severe pain (Kalso, 2005). Oxycodone is effective in severe chronic pain, whether nociceptive, cancer-related or neuropathic pain (Watson and Babul, 1998; Gimbel et al., 2003; Watson et al., 2003; Coluzzi and Mattia, 2005; Riley et al., 2008).

Like all opioids, oxycodone can be associated with the development of bowel dysfunction, which encompasses symptoms including bloating, abdominal spasm and cramps and constipation (Pappagallo, 2001). Constipation is the most frequently reported

adverse effect in patients receiving chronic opioid therapy (Thorpe, 2001; Coluzzi and Mattia, 2005), and is mediated mainly through stimulation of opioid receptors in the gastrointestinal tract. Opioids reduce motility (propulsive peristalsis) and secretion (water and electrolytes) (DeLuca and Coupar, 1996). Fluid absorption is also increased due to the increase in transit time (Holzer, 2007). These local actions in the intestine lead to the development of constipation, which represents a significant clinical problem.

Opioid-induced constipation can be so severe that some patients opt to discontinue therapy; this results in analgesic undertreatment, severely impairing quality of life (Derby and Portenoy, 1998; Cherny et al., 2001; Kurz and Sessler, 2003; Wirz and Klaschik, 2005). In patients who remain on therapy, frequent opioid dose reductions limit efficacy. Tolerance to opioid-induced

* Corresponding author.

E-mail address: petra.leyendecker@mundipharma-rd.eu (P. Leyendecker).

constipation rarely develops (Swegle and Logemann, 2006). Furthermore, as opioids inhibit gastrointestinal transit at doses much lower than those needed to produce analgesia (Shook et al., 1987), this side effect cannot be managed by reducing opioid dose. A significant proportion of patients who receive opioids on a long-term basis require treatment with a laxative. In a survey of 76 patients treated with opioids for non-cancer related pain, 88% used at least one treatment for constipation, while 58% received two or more (Pappagallo, 2001). In a retrospective study of 206 patients undergoing opioid therapy in palliative care, constipation was treated prophylactically or therapeutically with laxatives in 74.3% of patients (Wirz and Klaschik, 2005). However, laxatives do not address the underlying pathological cause of opioid-induced constipation, and it therefore persists in many patients (Pappagallo, 2001; Kurz and Sessler, 2003). Consequently, an effective therapeutic strategy to manage opioid-induced constipation is to prevent, rather than to treat it (Kurz and Sessler, 2003).

Naloxone is a pure opioid receptor antagonist commonly used intravenously to reverse opioid overdose. Although relatively well absorbed after oral administration, it undergoes extensive first-pass metabolism (glucuronidation) (De Schepper et al., 2004). Following oral administration, naloxone has a low oral bioavailability of <2%. It undergoes extensive hepatic metabolism to form the partly active metabolite 6 β -naloxol and glucuronides of naloxone and 6 β -naloxol (Weinstein et al., 1971). Consequently, orally administered naloxone has dose-dependently negligible systemic bioavailability at the concentrations used in the present study – its central effects are none or minimal but it can exert a full, local inhibitory effect on opioid receptors in the intestine. The primary local effect of naloxone is at the local intestinal wall, presumably at the site of the opioid receptors in the myenteric plexus and other neural and endocrine cells in the intestine (Kreek et al., 1983; Culpepper-Morgan et al., 1992). The co-administration of naloxone and oxycodone could therefore provide full analgesia while preventing, or minimising, opioid-induced constipation.

This Phase II trial was conducted to assess the impact of orally administered PR naloxone on the analgesic efficacy of PR oxycodone and opioid-induced constipation in patients with severe chronic pain. The study also allowed the determination of the most appropriate dose ratio for a fixed, PR oxycodone/naloxone combination tablet.

2. Methods

2.1. Patients

This was a multicentre, prospective, placebo-controlled, randomised, double-blind, parallel-group Phase II trial conducted in 28 centres in Germany from May 2002 to April 2003. The study was conducted in accordance with the Declaration of Helsinki and its successors (Edinburgh, 2000 and Washington, 2002) and complied with the principles of Good Clinical Practice set by the International Conference on Harmonization and applicable German regulatory requirements. Written informed consent was obtained from patients at screening.

Male and female patients aged 18 years old or over were eligible to take part in the study if they were experiencing severe chronic pain, as assessed by the investigator, of mainly non-cancer origin (2.5% of patients had cancer-related pain) that required opioid treatment, or they were under current stable PR oxycodone therapy (40, 60 or 80 mg/day). Exclusion criteria included current alcohol or drug abuse, current acute pancreatitis, current severe cardiovascular or respiratory diseases (e.g., lung cancer or metastases), current severe renal or liver impairment (transaminase levels three times above normal range), liver or renal carcinoma or metastases. Patients were also excluded if they had a history of paralytic ileus, psychoses or Parkinson's disease, a known hypersensitivity to one of the study drugs or had participated in another clinical study within 30 days of study entry. Female patients of childbearing age without adequate contraception, or those who were pregnant or lactating, were excluded.

2.2. Procedures

The study had three phases: pre-randomisation (which consisted of screening and titration/run-in), a double-blind treatment period (maintenance phase), and an open-label phase (Fig. 1).

Following screening, patients entered either a titration or run-in period. Patients with inadequate pain control (indicated through a non-formal discussion between the investigator and patient), or those who were receiving an opioid other than oxycodone, entered a titration period and were individually titrated and stabilised at an oxycodone PR dose of 40, 60 or 80 mg/day. Patients on a stable oxycodone pretreatment dose of 40, 60 or 80 mg/day, with concomitant constipation (with or without laxative intake), entered




Fig. 1. Study design. The study consisted of three phases: pre-randomisation, maintenance and an open-label phase. Six study visits were planned (V1–V6) and assessments made at V3, 1 week into the maintenance phase (V4), V5 and V6.

a 7-day run-in period and were eligible for the maintenance phase without prior titration. For those patients who entered the titration phase, the starting dose of oxycodone was determined based on their previous analgesic.

At the end of the 2-week titration or the 7-day run-in period, patients were eligible to enter the double-blind treatment period (maintenance phase) if they were on a stable daily oxycodone dose of 40–80 mg for 7 consecutive days, received no more than five rescue medications per week (each defined as one 10 mg PR oxycodone tablet) and required laxatives to have at least three bowel evacuations per week. During the maintenance phase, rescue medication was restricted to a maximum of five intakes of 10 mg oxycodone per week.

Throughout the pre-randomisation phase, laxatives could be taken as needed. Patients were subsequently advised to stop laxative intake at the beginning of the maintenance phase; however, it could be restarted if no bowel evacuations occurred within 3 days of the start of the maintenance phase.

For the maintenance phase, patients were randomised to four study groups. The randomisation program balanced the relation between four naloxone dose groups (10, 20, 40 mg or placebo) in block sizes of four (1:1:1:1 randomisation). The dosing groups and ratios are shown in Table 1.

For each patient, the total study duration was up to 10 weeks, including the screening period, a minimum 2-week titration period (or a 1-week run-in period), a 4-week treatment period and an open-label phase of 2 weeks, when patients stopped taking naloxone but continued oxycodone therapy. In total, six visits (V1–V6) were planned and compulsory telephone contact was maintained every second day during titration/run-in, to assess pain control and make dose changes if necessary.

At screening, medical histories of patients were obtained. Standard physical examination and clinical laboratory evaluations were also conducted at screening and during the pre-randomisation and maintenance phases. These included haematology, blood chemistry and liver function tests, as well as urinalysis and measurement of glucose, total albumin, creatinine and uric acid levels.

The primary efficacy outcomes of interest were mean pain and mean bowel function. Pain was assessed subjectively using a numerical analogue scale (NAS) where 0 = no pain and 100 = worst imaginable pain. The NAS was completed twice daily by each patient (in their diary) in the morning, and in the evening 2 h after study medication intake. At screening and baseline (V2), pain was assessed by the investigator. At V3 (end of titration/run-in, start of maintenance), mean pain intensity was calculated from all values recorded during the last 7 days in the patient diary. Similar measurements were made at the end of the maintenance (V5) and open-label (V6) phases.

Mean bowel function was based on patients' subjective assessment during the last 7 days prior to each visit, and was calculated from the mean NAS of the three distinct components of the bowel function index (BFI) (Fig. 2). Higher scores indicate poor bowel function. Assessments were made at four different time points: V3, one week into maintenance (V4), V5 and V6.

Secondary efficacy outcomes associated with pain were daily pain intensity (mean of morning and evening measurements – calculated from NAS values in the patient diary) and amount of rescue medication (recorded daily in the patient diary). Those associated with bowel function included ease of defaecation (NAS), a feeling of incomplete bowel evacuation (NAS), patient judgment of constipation (NAS), stool frequency (patient diary) and laxative intake (study report entries; laxatives were identified by the WHO ATC code A06A).

Safety assessments, including physical examination, standard laboratory tests (as described above) and monitoring and recording of all adverse events were performed at each visit.

2.3. Statistical analysis

To test for non-inferiority regarding pain relief, one-sided *t*-tests of the absolute dose of naloxone versus placebo, with an equivalence limit of 8 on a NAS of 0–100 (defined as a clinically non-relevant difference), were conducted for mean pain during the last 7 days before the end of the maintenance phase visit (after 4 weeks of naloxone treatment). Two-sided 90% confidence intervals (CI) for the difference in means between the treatment groups were provided. In order to take imbalances in mean pain intensity at baseline into account, a post hoc ANCOVA analysis of the mean pain intensity with baseline value as covariate was conducted. For the analysis of the secondary endpoints, a Wilcoxon test was used to test for treatment differences for the absolute dose of naloxone.

To test for difference of absolute dose of naloxone versus placebo with respect to bowel function variables, *t*-tests were performed for the values obtained during the end of maintenance phase. In addition, two-sided 95% CIs for the difference in means between the treatment groups were provided. Summary statistics for the three components of mean bowel function were provided for each study visit for all analysis groupings. Wilcoxon tests of absolute dose of naloxone versus placebo were performed in the ITT population for mean values at V4 and V5.

Response surface analyses for pain intensity and bowel function were also performed for the end of the maintenance phase and displayed as response surface plots. The model included baseline values (mean during the last 7 days prior to randomisation) as a covariate, and oxycodone and naloxone doses as factors. The analysis was done twice: once with the stable oxycodone dose at the beginning of the maintenance phase (40 mg/day, 60 mg/day, 80 mg/day), and once with the oxycodone dose calculated as the mean of the total oxycodone doses per day (including rescue medication) during the last 7 days before the respective visit, during or at the end of the maintenance phase. The model-estimated responses were tabulated. The analysis was performed using the Statistical Analysis Software (SAS), Version 8.2.

The quadratic response surface model was used, as it provides not only results for all dose groups but also for the whole dose range, including doses in between. The values of all dose groups were included in the statistical model resulting in an extensive data pool, which leads to more precise information on the 2:1 dose ratio. This approach allows derivation of more information from

Table 1
Oxycodone and naloxone dose groups

	Group 1	Group 2	Group 3	Group 4
Naloxone daily dose (mg)	Placebo	10	20	40
Oxycodone daily dose (mg)	40, 60, 80	40, 60, 80	40, 60, 80	40, 60, 80
Oxycodone/naloxone dose ratio	40/Placebo	40/10, 4:1	40/20, 2:1	40/40, 1:1
	60/Placebo	60/10, 6:1	60/20, 3:1	60/40, 1.5:1
	80/Placebo	80/10, 8:1	80/20, 4:1	80/40, 2:1

Medication was taken in two doses (12-hourly) or divided by substance.

Fig. 2. The bowel function index (BFI) is a three-item questionnaire to measure constipation from the patient's perspective. Instructions for administering each item of the BFI are indicated in the grey sections below each item. Subjects are asked each item in the BFI in the form of a question. If the subject does not understand what the question is asking, clarification may be provided by restating the question as indicated in the grey section. The subject's response to each question is written in the space provided. Study personnel confirm each answer provided by the subject by signing the review box below each question. To avoid any form of response bias, study personnel must not lead the subjects in their answers (e.g., study personnel should not provide examples of answers to a given question).

For the safety analysis, all continuous variables were summarised using descriptive statistics. Adverse events were summarised by the absolute number and percentage of patients on a system organ class and preferred term level (MedDRA). In addition, the number of patients and the number of adverse event occurrences were provided by seriousness, severity and relationship.

From the participating 28 centres, a total of 230 patients were screened; 202 were subsequently randomised and treated, and 166 completed the study (Fig. 3). A centre effect could not be observed, as assessed by a post hoc mixed model analysis. All randomised patients received study medication and were included in the safety population. For the per-protocol and safety analyses, only non-missing values were taken into account. An intent-to-treat (ITT) analysis was performed for all efficacy endpoints. The ITT population was defined as all randomised patients who received at least one dose of naloxone or corresponding naloxone placebo and had at least one efficacy assessment, and consisted of 196 (97.0%) patients. Six patients were excluded from the ITT population but included in the safety population for analysis of safety endpoints. Of these, five patients were excluded due to missing post-baseline efficacy assessments, and one patient received two different naloxone doses during the course of the study. For

All treatment groups and dose ratio groups were generally well balanced regarding demographic and baseline characteristics (Table 2). No clinically relevant differences between the treatment groups or dose ratios concerning prior or concomitant medications were noted. Back pain was the most common pain-causing disease (24.3%), followed by post-operative complications (15.3%).

The differences between naloxone placebo treatment and the 10 mg, 20 mg and 40 mg naloxone treatments were small, with the 90% CIs for the differences being narrow relative to the 0–100 pain scale. The 90% CIs for the differences based on an ANCOVA test with V3 pain as covariate were similarly narrow: -2.0




Fig. 3. Patient disposition. Of the 230 patients screened for the study, 202 were randomised for treatment and 166 completed the study. Reasons for discontinuation are shown.

Table 2
Patient demographics and baseline characteristics

Characteristic	Absolute dose of naloxone				Total (n = 202)
	Placebo (n = 50)	Naloxone 10 mg (n = 51)	Naloxone 20 mg (n = 51)	Naloxone 40 mg (n = 50)	
Sex, n (%)					
Male	19 (38.0)	18 (35.3)	17 (33.3)	21 (42.0)	75 (37.1)
Female	31 (62.0)	33 (64.7)	34 (66.7)	29 (58.0)	127 (62.9)
Mean age (years)	53.8	58.4	56.0	57.0	56.3
Pain-causing disease, n (%)					
Back pain	11 (22.0)	16 (31.4)	14 (27.5)	8 (16.0)	49 (24.3)
Fibromyalgia	3 (6.0)	5 (9.8)	2 (3.9)	5 (10.0)	15 (7.4)
Intervertebral disc herniation	6 (12.0)	3 (5.9)	2 (3.9)	3 (6.0)	14 (6.9)
Neck pain	2 (4.0)	2 (3.9)	3 (5.9)	1 (2.0)	8 (4.0)
Neuropathic pain	2 (4.0)	2 (3.9)	0 (0.0)	3 (6.0)	7 (3.5)
Pain	3 (6.0)	3 (5.9)	2 (3.9)	3 (6.0)	11 (5.4)
Post-operative complications	11 (22.0)	6 (11.8)	5 (9.8)	9 (18.0)	31 (15.3)
Sciatica	0 (0.0)	2 (3.9)	4 (7.8)	2 (4.0)	8 (4.0)
Spinal stenosis	1 (2.0)	4 (7.8)	4 (7.8)	2 (4.0)	11 (5.4)
Tumor patients	1 (2.0)	1 (2.0)	1 (2.0)	2 (4.0)	5 (2.5)
Mean duration of pain (months)	149.3	113.1	154.7	136.7	138.6

to 8.2, -6.7 to 4.0 and -3.3 to 7.4 for 10 mg, 20 mg and 40 mg naloxone, respectively, versus placebo. The differences in the intensity of mean pain between the dose ratio groups were also very small (data not shown); however, given the small patient populations in each group, a statistical analysis was not conducted.

Results obtained in the per-protocol population were generally mirrored by those of the ITT population for the analysis of intensity of mean pain. Overall, the results indicate that the addition of naloxone did not reduce the analgesic efficacy of oxycodone.

The other primary efficacy outcome in this study was bowel function. Scores obtained from the BFI decreased as the naloxone dose increased (Fig. 5). At V4, the difference between 40 mg naloxone and placebo was statistically significant ($p = 0.004$), while at the end of maintenance (V5) the differences for both the 20 mg and 40 mg doses of naloxone and placebo were statistically significant ($p < 0.05$). According to the analysis by dose ratio, at the end of the maintenance phase (V5), mean ($\pm$ SD) bowel function score was lowest in the 1:1, 1.5:1 and 2:1 dose ratios: 21.9 ($\pm$ 22.25), 21.8 ($\pm$ 21.35) and 26.7 ($\pm$ 23.98), respectively.




Fig. 4. Mean pain intensity at each study visit by absolute naloxone dose (per-protocol population) (NAS score: 0 = no pain, 100 = worst imaginable pain). There were no significant differences in mean pain intensity between the treatment groups at any of the study visits.




Fig. 5. Mean bowel function at each study visit (ITT population) as measured using the bowel function index (BFI). Increasing scores reflect increasing severity of bowel dysfunction. At Visit 4 there was a significant improvement in bowel function for the 40 mg naloxone group compared with placebo ($p = 0.004$). Both the 20 mg and 40 mg naloxone dose groups showed significant improvements in bowel function compared with placebo at Visit 5 ($p < 0.05$).

The removal of naloxone from the treatment regimen at the end of the maintenance phase resulted in an increase in the BFI score, indicating a worsening of bowel dysfunction. At the end of the open-label phase (V6), BFI scores had almost returned to baseline values (Fig. 5).

The post hoc analysis confirmed the original statistical analysis. The analysis of model-estimated responses also showed that bowel function remains relatively constant within the oxycodone/naloxone dose ratio, but decreases as the amount of naloxone decreases, within the same absolute oxycodone dose. This was confirmed by the surface plot for bowel function versus daily naloxone and oxycodone doses (Fig. 6).

Overall treatment effect estimates were obtained for specific ratios. The estimates were calculated by combining the results from the different oxycodone/naloxone combinations; for example, the 2:1 ratio estimate was formed by averaging the predicted results of the 40/20 mg, 60/30 mg, and 80/40 mg oxycodone/naloxone combinations, relative to naloxone placebo. The estimated mean differences (SE) in mean bowel function for various oxycodone/naloxone ratios versus naloxone placebo groups are shown in Table 3. The estimates indicate that bowel function improves progressively as the oxycodone/naloxone ratio decreases, with the estimated improvement at 2:1 approximately 50% higher than at 4:1 ($p < 0.05$) and with a minimal improvement from the 2:1 ratio to the 1.5:1 ratio.

The main secondary efficacy outcome for the pain component of the study was daily pain intensity. This was shown to be stable for all treatment groups throughout the course of the maintenance phase. The demand for rescue medication also remained stable throughout the study period. No identifiable trend was observed in the numbers of patients taking rescue medication across all treatment groups.

Secondary efficacy outcomes for the bowel function component were the individual components of the BFI, stool frequency and laxative intake.


Table 3
Response surface analysis of bowel function efficacy (BFI) by oxycodone/naloxone ratio: estimated improvement (SE)/difference versus naloxone placebo at V5

Oxycodone/naloxone ratio	Overall improvement (SE) versus placebo
6:1	8.0 (3.3)
4:1	11.0 (4.1)
3:1	13.4 (4.6)
2:1	16.2 (4.5)
1.5:1	16.5 (5.1)

For each treatment group there was an increase in stool frequency (per day), with increasing doses of naloxone during the last 7 days before V4; the mean ($\pm$ SD) values were 0.9 ($\pm$ 0.46), 1.0 ($\pm$ 0.48), 1.2 ($\pm$ 0.82), 1.4 ($\pm$ 0.63) for placebo, 10 mg, 20 mg and 40 mg, respectively ($p < 0.001$ for 40 mg versus placebo). A similar pattern was also observed at V5, the mean ($\pm$ SD) values being 0.9 ($\pm$ 0.46), 1.0 ($\pm$ 0.48), 1.0 ($\pm$ 0.45), 1.1 ($\pm$ 0.59) for placebo, 10 mg, 20 mg and 40 mg, respectively, with a statistically significant difference to placebo ($p < 0.05$) obtained for 40 mg naloxone. The mean ($\pm$ SD) number of days with laxative intake during the last 7 days of the maintenance phase decreased with increasing absolute dose of naloxone: 3.9 ($\pm$ 3.38), 2.6 ($\pm$ 3.34), 2.0 ($\pm$ 3.14), 1.6 ($\pm$ 2.93) for placebo, 10 mg, 20 mg and 40 mg naloxone, respectively ($p < 0.001$ for all doses of naloxone versus placebo). The number of patients taking laxatives within that timeframe was 35 (81%), 26 (70%), 18 (45%), 21 (58%) for placebo, 10 mg, 20 mg and 40 mg naloxone, respectively.

A total of 202 patients were included in the safety analysis. No trends or possible treatment-related pathological laboratory findings could be identified for any of the treatment groups. No deaths occurred during the study.

During the maintenance phase, the incidence of adverse events was comparable across all treatment groups (range 62.7–70.0%), although the number of events increased with increasing naloxone



Oxycodone PR/naloxone PR dose ratio	40 mg/ placebo	60 mg/ placebo	80 mg/ placebo	1/1	1.5/1	2/1	3/1	4/1	6/1	8/1
n	17	17	16	15	17	32	17	32	11	22

Fig. 6. Response surface plot (ITT population) of mean bowel function at V5 (end of the maintenance phase) versus daily naloxone and oxycodone doses shows that bowel function remains relatively constant within the oxycodone/naloxone dose ratio, but decreases as the amount of naloxone decreases, within the same absolute oxycodone dose.

Table 4
Overall summary of adverse events by absolute naloxone dose during the maintenance phase

	Naloxone placebo		10 mg Naloxone		20 mg Naloxone		40 mg Naloxone	
	Patients	Events	Patients	Events	Patients	Events	Patients	Events
	n = 50 (100%)	n	n = 51 (100%)	n	n = 51 (100%)	n	n = 50 (100%)	n
Number (%) of patients with at least one adverse event	32 (64.0%)	111	35 (68.6%)	119	32 (62.7%)	129	35 (70.0%)	140
Mild	23 (46.0%)	76	23 (45.1%)	62	22 (43.1%)	65	24 (48.0%)	64
Moderate	13 (26.0%)	32	17 (33.3%)	40	19 (37.3%)	42	21 (42.0%)	52
Severe	2 (4.0%)	3	8 (15.7%)	17	8 (15.7%)	22	11 (22.0%)	24

dose – 111, 119, 129 and 140 events for the placebo, 10 mg, 20 mg and 40 mg naloxone doses, respectively. No relationship to dose ratio was identified. Most adverse events were mild or moderate in intensity. There was a slight trend for an increase in moderate and severe adverse events with increasing naloxone dose (Table 4), but the incidence of serious adverse events was low and generally comparable across all active naloxone treatment groups.

The only difference in the incidence of adverse events between dose ratio treatment groups was the incidence of diarrhoea – this was 50% in the 1.5:1 dose ratio group, but substantially less (29.4%), in the 2:1 dose ratio group. The incidence of diarrhoea was higher among patients taking active naloxone and increased with higher doses; 12.0%, 19.6%, 23.5% and 36.0% for placebo, 10 mg, 20 mg and 40 mg naloxone groups, respectively.

Overall, the frequency of discontinuations due to adverse events during the maintenance phase increased with an increasing dose of naloxone; 2.0%, 9.8%, 11.8% and 18.0% for the placebo, 10 mg, 20 mg and 40 mg naloxone groups, respectively. The main reason for discontinuation in the naloxone 20 mg and 40 mg treatment groups was related to diarrhoea: 0.0%, 2.0%, 7.8% and 12.0% patients discontinued in the placebo, 10 mg, 20 mg and 40 mg naloxone treatment groups, respectively. Study discontinuation due to diarrhoea was related to its severity or the degree of discomfort caused in patients, not duration. In patients who did not withdraw from the study, diarrhoea as a side effect was transient.

4. Discussion

Results from this clinical trial indicate that the analgesia provided by PR oxycodone co-administered with PR naloxone is comparable to that of PR oxycodone administered alone, and significantly reduces the impact of opioid-induced constipation. During the maintenance phase, the addition of naloxone did not lead to the worsening of pain – no apparent differences in the intensity of daily pain were observed between any of the treatment groups, indicating that there was no interference of naloxone with the analgesic effect of oxycodone. Analysed by absolute naloxone dose, mean pain scores with naloxone were equivalent to placebo. The lack of effect of naloxone on the analgesic efficacy of oxycodone is further demonstrated by the observation that the demand for rescue medication in all treatment groups remained stable throughout the study period.

At V5 (end of the maintenance phase) mean bowel function scores were the lowest for all treatment groups, indicating that the addition of PR naloxone to the PR oxycodone regimen of patients significantly reduced the severity of bowel dysfunction. This improvement in bowel function was dose dependent – the severity of opioid-induced constipation was reduced progressively as the oxycodone/naloxone ratio decreased. The small improvement observed in the naloxone placebo group was negligible. Overall, the dose-dependent improvement in bowel function indicates a naloxone-specific effect. As expected, analysis of the secondary endpoints revealed similar findings to the primary endpoint – improvements in the individual measurements of bowel dysfunction

(ease of defaecation, feeling of incomplete bowel evacuation and judgment of constipation) were noted, with the greatest improvements seen at dose ratios of 1:1, 1.5:1 and 2:1 or an absolute naloxone dose of 40 mg. Stool frequency also increased with an increase in naloxone dose, while the use of laxatives decreased. All improvements decreased after termination of the maintenance phase, indicating that continuous naloxone treatment might be necessary in order to maintain normal bowel function.

Modelled estimates of overall treatment effect for specific ratios indicated that the estimated improvement at 2:1 was approximately 50% higher than at 4:1 ($p < 0.05$). However, there was only minimal improvement from the 2:1 ratio to the 1.5:1 ratio – this indicates that improvement in bowel function may reach a plateau, which can be achieved with the 2:1 ratio. Based on the analysis of the efficacy and safety results by dose and dose ratio, the 2:1 ratio with a 40 mg maximum daily dose of naloxone was deemed optimal with regard to efficacy and tolerability and best suited for further evaluation. The mean ($\pm$ SD) number of days with laxative intake during the last 7 days of the maintenance phase decreased with increasing absolute dose of naloxone: 3.9 ($\pm$ 3.38), 2.6 ($\pm$ 3.34), 2.0 ($\pm$ 3.14), 1.6 ($\pm$ 2.93) for placebo, 10 mg, 20 mg and 40 mg naloxone, respectively. Still, laxatives were used even with the highest naloxone dose. Naloxone can only reduce or prevent opioid-induced constipation. Laxatives may still be needed to alleviate constipation caused by other medication or idiopathic constipation.

The safety profile of oxycodone and naloxone are well established. Nausea, vomiting and sedation are typical opioid-related adverse events, while abdominal pain, cramping and diarrhoea are typically associated with naloxone use. Both agents, when co-administered during the maintenance phase of this trial were well tolerated – adverse events, beyond the nature and severity of those expected, were not reported. The safety profiles of all treatment arms were comparable; the only exception with regard to adverse events was diarrhoea, which increased with increasing naloxone dose. However, this side effect was transient in the majority of patients who suffered from it, and might be considered as an 'overshoot' effect.

The use of immediate-release oral naloxone has been previously studied to ascertain its effect in reducing opioid-induced constipation; however, the study populations have been small and the results equivocal (Sykes, 1996; Meissner et al., 2000; Liu and Wittbrodt, 2002; Latasch et al., 1997). In some of these trials, withdrawal symptoms were observed even at low doses of oral naloxone. In the current trial PR naloxone was used. The slow release of naloxone might reduce the risk of overburdening the hepatic enzymatic systems responsible for its metabolism, thereby reducing the risk of systemic antagonism. The results provide strong evidence that the addition of PR oral naloxone to an opioid-based analgesic regimen does not reduce the efficacy of the opioid. The negative impact of opioid-induced constipation is often overlooked and under-appreciated; it is one of the most common reasons patients avoid or abandon opioid use and, consequently, suffer from pain needlessly (Thorpe, 2001). Furthermore, if opioid-induced constipation is not addressed adequately, it can, in itself

become a cause of pain, thus increasing opioid use and generating a positive feedback loop (Tamayo and Diaz-Zuluaga, 2004).

Further studies investigating the efficacy and safety of the combination are ongoing. In addition, mucosal lesions, gastric emptying and regurgitation are interesting endpoints in opioid-induced bowel dysfunction that could be included in future studies.

A combination of the strong opioid oxycodone with naloxone in a PR formulation could allow patients suffering from chronic pain to receive adequate analgesia on a long-term basis and to maintain normal bowel function.

An oxycodone/naloxone combination will also be of great benefit to healthcare professionals who are responsible for the care of patients with severe chronic pain. With the reduced incidence of opioid-induced constipation and subsequent need for laxatives, or sometimes even more severe interventions such as enemas and manual evacuations, the management of patients can be improved. The availability of a strong opioid with an improved tolerability profile, such as a fixed 2:1 oxycodone/naloxone combination, has significant added therapeutic value, thus representing a major advance in the treatment and quality of life of patients suffering from severe chronic pain.

Acknowledgements

The study was designed by Mundipharma GmbH, and conducted by qualified investigators under the sponsorship of Mundipharma GmbH. Data were gathered by the sponsor and evaluated jointly by the authors and the sponsor. All authors were involved in the development and writing of the manuscript. The authors thank Dr. Azita Tofighy, who provided medical writing services on behalf of Mundipharma GmbH. The corresponding author takes responsibility for the integrity and the accuracy of the data analysis, and also had final responsibility for the decision to submit for publication.

References

- Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. *J Clin Oncol* 2001;19:2542–54.
- Coluzzi F, Martia C. Oxycodone. Pharmacological profile and clinical data in chronic pain management. *Minerva Anestesiol* 2005;71:451–60.
- Culpepper-Morgan JA, Incirrisi CE, Portenoy RK, Foley K, Houde RW, Marsh F, et al. Treatment of opioid-induced constipation with oral naloxone: a pilot study. *Clin Pharmacol Ther* 1992;52:90–5.
- DeLuca A, Coupar IM. Insights into opioid action in the intestinal tract. *Pharmacol Ther* 1996;69:103–12.
- Derby S, Portenoy RK. Assessment and management of opioid-induced constipation. In: Portenoy RK, Bruera E, editors. *Topics in palliative care 1*. New York: Oxford University Press; 1998. p. 95–112.
- De Schepper HU, Cremonini F, Park M, Camilleri M. Opioids and the gut: pharmacology and current clinical experience. *Neurogastroenterol Motil* 2004;16:383–94.
- Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. *Neurology* 2003;60:927–34.
- Holzer P. Treatment of opioid-induced gut dysfunction. *Expert Opin Investig Drugs* 2007;16(2):181–94.
- Kalso E. Oxycodone. *J Pain Symptom Manage* 2005;29(Suppl. 5):S47–56.
- Kreek MJ, Schaefer RA, Hahn EF, Fishman J. Naloxone, a specific opioid antagonist, reverses chronic idiopathic constipation. *Lancet* 1983;1:261–2.
- Kurz A, Sessler DL. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. *Drugs* 2003;63:649–71.
- Latasch L, Zimmermann M, Eberhardt B, Juma I. Treatment of morphine-induced constipation with oral naloxone. *Anaesthesist* 1997;46:191–4.
- Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. *J Pain Symptom Manage* 2002;23:48–53.
- Melssner W, Schmidt U, Hartmann M, Kath R, Reinhart K. Oral naloxone reverses opioid-associated constipation. *Pain* 2000;84:105–9.
- Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. *Am J Surg* 2001;182(SA Suppl.):11S–8S.
- Riley J, Eisenberg E, Müller-Schwefe G, Drewes AM, Arendt-Nielsen L. Oxycodone: a review of its use in the management of pain. *Curr Med Res Opin* 2008;24(1):175–92.
- Shook JE, Pelton JT, Hruby VJ, Burks TF. Peptide opioid antagonist separates peripheral and central opioid antitranst effects. *J Pharmacol Exp Ther* 1987;243:492–500.
- Swagie JM, Logemann C. Management of common opioid-induced adverse effects. *Am Fam Physician* 2006;74:1347–54.
- Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. *Palliat Med* 1996;10:135–44.
- Tamayo AC, Diaz-Zuluaga PA. Management of opioid-induced bowel dysfunction in cancer patients. *Support Care Cancer* 2004;12:613–8.
- Thorpe DM. Management of opioid-induced constipation. *Curr Pain Headache Rep* 2001;5:237–40.
- Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. *Pain* 2003;105:71–8.
- Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. *Neurology* 1998;50:1837–41.
- Weinstein SH, Pfeiffer M, Schor JM, Indindoli L, Mintz M. Metabolites of naloxone in human urine. *J Pharm Sci* 1971;60:1567–8.
- Witz S, Klaschik E. Management of constipation in palliative care patients undergoing opioid therapy: Is polyethylene glycol an option? *Am J Hosp Palliat Care* 2005;22:375–81.